Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection

Journal of Infection

Volumn 57, Issue 3, 2008, Pages 191-197

  Ruparelia, N ^a   Atkins, B L ^a,b   Hemingway, J ^a   Berendt, A R ^a   Byren, I ^a,b  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Osteoarticular infection; Osteomyelitis; Pristinamycin; Prosthetic joint infection

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; FLUCONAZOLE; FUSIDATE SODIUM; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MEROPENEM; METICILLIN; MINOCYCLINE; NETILMICIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BONE INFECTION; CLINICAL ARTICLE; DEBRIDEMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAM POSITIVE BACTERIUM; HEART INFARCTION; HUMAN; LETHARGY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OSTEOARTHROPATHY; PHOTOSENSITIVITY; PRESCRIPTION; PROSTHESIS INFECTION; RECURRENT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PRISTINAMYCIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 50449099689     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.07.002     Document Type: Article

References (32)

1. Atkins B.L., Athanasou N., Deeks J.J., Crook DWM., Simpson H., Peto TEA., et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic joint infection at revision arthroplasty. J Clin Microbiol 36 10 (1998) 2932-2939
2. Zimmerli W., Frei R., Widner A., and Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 33 (1994) 959-967
3. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. Role of rifampicin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279 19 (1998 May 20) 1537-1541
4. Green S.L., Maddox J.C., and Huttenbach E.D. Linezolid and reversible myelosuppression. JAMA 285 (2001) 1291
5. Bressler A.M., Zimmer S.M., Gilmore J.L., and Somani J. Peripheral neuropathy associated with the prolonged use of linezolid. Lancet Infec Dis 4 8 (2004) 528-531
6. Coenen S., Ferech M., Malhotra-Kumar S., Hendrickx E., Suetens C., and Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 58 2 (2006) 418-422 [Epub 2006 May 30]
7. Paris J.M., Barriere J.C., Smith C., and Bost PE. The chemistry of pristinamycins. In recent progress in the chemical synthesis of antibiotics (1990), Springer-Verlag, Berlin p. 185-245
8. Barriere J.C., Berthaud N., Beyer D., Dutka-Malen S., Paris J.M., and Desnottes J.F. Recent developments in streptogramin research. Curr Pharm Des 4 2 (1998) 155-180
9. Leclerq R., Soussy C., Weber P., Moniot-Ville N., and Dib C. In vitro activity of pristinamycin against isolated Staphylococci in French Hospitals in 1999-2000. Path Biol 51 7 (2003) 400-404
10. Fass R.J. In vitro activity of RP59500, a semisynthetic injectable pristinamycin against Staphylococci, Streptococci and Enterococci. Antimicrob Agents Chemother 30 Suppl. A (1991) 29-37
11. Weber P. Streptococcus pneumoniae: lack of emergence of pristinamycin resistance. Pathol Biol 49 10 (2001) 840-845
12. Mutton K.J., and Andrew J.H. In vitro activity of pristinamycin against methicillin-resistant Staphylococcus aureus. Chemotherapy 29 (1983) 218-224
13. Collins L.A., Malanoski G.J., Eliopoulos G.M., Wennersten C.B., Ferraro M.J., and Moelering Jr. R.C. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37 3 (1993) 598-601
14. Lefevre J.C., and Bauriaud R. Comparative in vitro activities of pristinamycin and other antimicrobial agents against genital pathogens. Antimicrob Agents Chemother 33 (1989) 2152-2154
15. Bernard L., Hoffmeyer P., Assal M., Vaudaux P., Schrenzel J., and Lew D. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother 53 (2004) 127-129
16. Rao N., Crossett L.S., Sinha R.K., and Le Frock J.L. Long term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res 414 (2003) 55-60
17. Goulet J.A., Pellicci P.M., Brause B.D., and Salvati E.M. Prolonged suppression of infection in total hip arthroplasty. J Arthroplasty 3 2 (1988) 109-116
18. Segreti J., Nelson J.A., and Trenholme G.M. Prolonged suppressive antibiotic therapy for infected orthopaedic prosthesis. Clin Infect Dis 27 (1998) 711-713
19. Moran E., Masters S., Berendt A.R., McLardy-Smith P., Byren I., and Atkins B.L. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect 55 1 (2007 Jul) 1-7 [Epub 2007 Mar 6]
20. Donaldson A.D., Raymond C.C., and Gosbell I.B. Community acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance. Med J Aust 184 4 (2006) 196
21. Quentin C., Grobost F., Fischer I., Dutilh B., Brochet JP., Jullin J., et al. Antibiotic resistance of Staphylococcal aureus in urban experience: 6 month study in Aquitaine. Pathol Biol 49 (2001) 33-40
22. Jan C., Grignon B., Gillet P., Pere P., Regent D., and Gaucher A. Arthrites septiques sterno-claviculaires: à propos de 4 observations récentes. Rhumatologie 46 7 (1994) 181-185
23. Roblot P., Gouet D., Alacaly M., and Bontoux. Les arthrites à pyogènes de la hanche de l'adulte. A propos de seize cas. Rhumatologie 39 7 (1987) 201-207
24. Bonfait H., Denormandie P., and Signoret F. Intérêt de la pristinamycine (pyostacine) dans les fractures ouvertes des membres. Ann Chir 40 3 (1986) 223-226
25. Beauvais P., Filipe G., Berniere J., and Carlioz H. Oral pristinamycin therapy for bone and joint infections in children. A report of 50 cases. Arch Fr Pediatr 38 7 (1981 Aug-Sep) 489-493
26. Debauchez C. La Pristinamycine dans le traitement des infections osteo-articulaires de l'enfant. Concours Med 104 7 (1982) 981-982
27. Boibieux A., Brechignac X., Bouhour D., Roure C., Tigaud S., and Peyramond D. Pristinamycin et infections osteo-articulaires: 4 ans de suivi. Med Mal Infect 31 Suppl. 3 (2001) 432s-473s
28. Pechere J.C. In-vitro activity of RP 59500, a semi synthetic streptogramin, against staphylococci and streptococci. J Antimicrob Chemother 30 Suppl. A (1992) 15-18
29. Brumfitt W., Hamilton-Miller J.M.T., and Shah S. In-vitro activity of RP 59500, a new semi synthetic streptogramin antibiotic, against Gram-positive cocci. J Antimicrob Chemother 30 Suppl. A (1992) 29-37
30. Ng J., and Gosbell I.B. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother 55 (2005) 1008-1012
31. Dancer S.J., Robb A., Crawford A., and Morrison D. Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. J Antimicrob Chemother 51 (2003) 731-735
32. Sanofi Aventis medicine information. http://www.sanofi-aventis.co.uk accessed 1st June 2007